Skip to main content
Log in

Dipeptidylpeptidase-4 Inhibitors (Gliptins)

Focus on Drug-Drug Interactions

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

An Erratum to this article was published on 01 January 2011

Abstract

Patients with type 2 diabetes mellitus (T2DM) are generally treated with many pharmacological compounds and are exposed to a high risk of drug-drug interactions. Indeed, blood glucose control usually requires acombination of various glucose-lowering agents, and the recommended global approachto reduce overall cardiovascular risk generally implies administration of several protective compounds, including HMG-CoA reductase inhibitors (statins), antihypertensive compounds and antiplatelet agents.

New compounds have been developed to improve glucose-induced gB-cell secretion and glucose control, without inducing hypoglycaemia or weight gain, in patients with T2DM. Dipeptidylpeptidase-4 (DPP-4) inhibitors are novel oral glucose-lowering agents, which may be used as monotherapy or in combination with other antidiabetic compounds, metformin, thiazolidinediones or even sulfonylureas. Sitagliptin, vildagliptin and saxagliptin are already on the market, either as single agents or in fixed-dose combined formulations with metformin. Other compounds, such as alogliptin and linagliptin, are in a late phase of development.

This review summarizes the available data on drug-drug interactions reported in the literature for these five DDP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin and linagliptin. Possible pharmaco-kinetic interferences have been investigated between each of these compounds and various pharmacological agents, which were selected because there are other glucose-lowering agents (metformin, glibenclamide [glyburide], pioglitazone/rosiglitazone) that may be prescribed in combination with DPP-4 inhibitors, other drugs that are currently used in patients with T2DM (statins, antihypertensive agents), compounds that are known to interfere with the cytochrome P450 (CYP) system (ketoconazole, diltiazem, rifampicin [rifampin]) or with P-glycoprotein transport (ciclosporin), or agents with a narrow therapeutic safety window (warfarin, digoxin). Generally speaking, almost no drug-drug interactions or only minor drug-drug interactions have been reported between DPP-4 inhibitors and any of these drugs. The gliptins do not significantly modify the pharmacokinetic profile and exposure of the other tested drugs, and the other drugs do not significantly alter the pharmacokinetic profile of the gliptins or exposure to these. The only exception concerns saxagliptin, which is metabolized to an active metabolite by CYP3A4/5. Therefore, exposure to saxagliptin and its primary metabolite may be significantly modified when saxagliptin is coadministered with specific strong inhibitors (ketoconazole, diltiazem) or inducers (rifampicin) of CYP3A4/5 isoforms. The absence of significant drug-drug interactions could be explained by the favourable pharmacokinetic characteristics of DPP-4 inhibitors, which are not inducers or inhibitors of CYP isoforms and are not bound to plasma proteins to a great extent. Therefore, according to these pharmacokinetic findings, which were generally obtained in healthy young male subjects, no dosage adjustment is recommended when gliptins are combined with other pharmacological agents in patients with T2DM, with the exception of a reduction in the daily dosage of saxagliptin when this drug is used in association with a strong inhibitor of CYP3A4/A5. It is worth noting, however, that a reduction in the dose of sulfonylureas is usually recommended when a DPP-4 inhibitor is added, because of a pharmacodynamic interaction (rather than a pharmacokinetic interaction) between the sulfonylurea and the DPP-4 inhibitor, which may result in a higher risk of hypoglycaemia. Otherwise, any gliptin may be combined with metformin or a thiazolidinedione (pioglitazone, rosiglitazone), leading to a significant improvement in glycaemic control without an increased risk of hypoglycaemia or any other adverse event in patients with T2DM. Finally, the absence of drug-drug interactions in clinical trials in healthy subjects requires further evidence from large-scale studies, including typical subjects with T2DM \3- in particular, multimorbid and geriatric patients receiving polypharmacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998; 55: 225–36

    Article  CAS  PubMed  Google Scholar 

  2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyper-glycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Dia-betologia 2009; 52: 17–30

    CAS  Google Scholar 

  3. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385–411

    Article  CAS  PubMed  Google Scholar 

  4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–705

    Article  CAS  PubMed  Google Scholar 

  5. Idris S, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diab Obes Metab 2007; 9: 153–65

    Article  CAS  Google Scholar 

  6. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; (2): CD006739

    Google Scholar 

  7. Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin: diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009; 23: 487–98

    Article  CAS  PubMed  Google Scholar 

  8. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010; 30: 463–84

    Article  CAS  PubMed  Google Scholar 

  9. Scheen AJ, Lefebvre PJ. Antihyperglycaemic agents: drug interactions of clinical importance. Drug Saf 1995; 12: 32–45

    Article  CAS  PubMed  Google Scholar 

  10. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005; 28: 601–31

    Article  CAS  Google Scholar 

  11. Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Exp Opin Drug Metab Toxicol 2009; 5: 225–41

    Article  CAS  Google Scholar 

  12. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007; 46: 93–108

    Article  CAS  PubMed  Google Scholar 

  13. Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007; 46: 1–12

    Article  CAS  PubMed  Google Scholar 

  14. Gupta R, Wallunj SS, Tokala RK, et al. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets 2009; 10: 71–87

    Article  CAS  PubMed  Google Scholar 

  15. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Metab Obes 2010; 12: 648–58

    Article  CAS  Google Scholar 

  16. Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010; 375: 1410–2

    Article  PubMed  Google Scholar 

  17. Scheen AJ. Current management of coexisting obesity and type 2 diabetes. Drugs 2003; 63: 1165–84

    Article  CAS  PubMed  Google Scholar 

  18. Ryden L, Standl E, Bartnik M, et al. Guidelines ondiabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136

    Article  CAS  PubMed  Google Scholar 

  19. American Diabetes Association. Standards of medical care in diabetes — 2010. Diabetes Care 2010; 33 (Suppl. 1): S11–61

    Article  PubMed Central  Google Scholar 

  20. European Medicines Agency. Januvia: European public assessment report. London: European Medicines Agency, 2009 Dec 8 [online]. Available from URL: http://www.ema.europa.eu/humandocs/Humans/EPAR/januvia/ja nuvia.htm [Accessed 2010 Jun 1]

  21. European Medicines Agency. Galvus: European public assessment report. Scientific discussion. London: European Medicines Agency, 2007 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf [Accessed 2010 Jun 1]

  22. European Medicines Agency. Committee for Medicinal Products for Human Use summary of positive opinion for Onglyza [document reference EMEA/ CHMP/369490/2009]. London: European Medicines Agency, 2009 Jun 25 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/opinion/Onglyza_36949009e.pdf [Accessed 2010 Jun 1]

  23. Lyseng-Williamson KA. Sitagliptin. Drugs 2007; 67: 587–97

    Article  CAS  PubMed  Google Scholar 

  24. Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 2007; 29: 2614–34

    Article  CAS  PubMed  Google Scholar 

  25. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 489–512

    Article  CAS  PubMed  Google Scholar 

  26. Reynolds JK, Neumiller JJ, Campbell RK. Janumet: a combination product suitable for use in patients with type 2 diabetes. Expert Opin Invest Drugs 2008; 17: 1559–65

    Article  CAS  Google Scholar 

  27. Chu XY, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007; 321: 673–83

    Article  CAS  PubMed  Google Scholar 

  28. Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 2008; 4: 743–51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359–71

    Article  CAS  PubMed  Google Scholar 

  30. Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006; 22: 1939–47

    Article  CAS  PubMed  Google Scholar 

  31. Krishna R, Bergman A, Larson P, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 2007; 47: 165–74

    Article  CAS  PubMed  Google Scholar 

  32. Mistry GC, Bergman AJ, Zheng W, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008; 66: 36–42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mistry GC, Bergman AJ, Luo WL, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007; 47: 159–64

    Article  CAS  PubMed  Google Scholar 

  34. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733–45

    Article  CAS  PubMed  Google Scholar 

  35. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safetyof the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556–68

    Article  CAS  PubMed  Google Scholar 

  36. Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag 2008; 4: 1221–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343–70

    Article  CAS  PubMed  Google Scholar 

  38. Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf 2003; 26: 13–21

    Article  CAS  PubMed  Google Scholar 

  39. Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 2009; 49: 483–8

    Article  CAS  PubMed  Google Scholar 

  40. Kao DP, Kohrt HR, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008; 25: 1229–30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Boucher BJ. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use: but what about the amiodarone? Diabet Med 2008; 26: 192–3

    Article  Google Scholar 

  42. DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential si-tagliptin-lovastatin interaction. Pharmacotherapy 2009; 29: 352–6

    Article  PubMed  Google Scholar 

  43. Wright D, Herman GA, Maes A, et al. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmaco-dynamics of warfarin. J Clin Pharmacol 2009; 49: 1157–67

    Article  CAS  PubMed  Google Scholar 

  44. Miller JL, Migoya E, Talaty JE, et al. The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects [abstract no. PI-65]. Clin Pharmacol Ther 2006; 79(2): P24 [online]. Available from URL: http://www.nature.com/clpt/journal/v79/n2/pdf/clpt2006100a.pdf [Accessed 2010 Jun 1]

    Article  Google Scholar 

  45. Henness S, Keam SJ. Vildagliptin. Drugs 2006; 66: 1989–2001

    Article  CAS  PubMed  Google Scholar 

  46. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2008; 68: 2387–409

    Article  CAS  PubMed  Google Scholar 

  47. Halimi S, Schweizer A, Minic B, et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008; 4: 481–92

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Tahrani AA, Piya MK, Barnett AH. Drug evaluation: vildagliptin-metformin single-tablet combination. Adv Ther 2009; 26: 138–54

    Article  CAS  PubMed  Google Scholar 

  49. He YL, Sabo R, Picard F, et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009; 25: 1265–72

    Article  CAS  PubMed  Google Scholar 

  50. He YL, Paladini S, Sabia H, et al. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects. Int J Clin Pharmacol Ther 2008; 46: 259–67

    Article  CAS  PubMed  Google Scholar 

  51. Serra D, He YL, Bullock J, et al. Evaluation of pharmacokinetic and phar-macodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with type 2 diabetes. Int J Clin Pharmacol Ther 2008; 46: 349–64

    Article  CAS  PubMed  Google Scholar 

  52. Ayalasomayajula SP, Dole K, He YL, et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvas-tatin in healthy subjects. Curr Med Res Opin 2007; 23: 2913–20

    Article  CAS  PubMed  Google Scholar 

  53. He YL, Sabo R, Riviere GJ, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007; 23: 1131–38

    Article  CAS  PubMed  Google Scholar 

  54. He YL, Sabo R, Sunkara G, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007; 47: 998–1004

    Article  CAS  PubMed  Google Scholar 

  55. El-Ouaghlidi A, Rehring E, Holst JJ, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007; 92: 4165–71

    Article  CAS  PubMed  Google Scholar 

  56. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sul-phonylurea. Diabetes Obes Metab 2008; 10: 1047–56

    Article  CAS  PubMed  Google Scholar 

  57. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166–74

    Article  CAS  PubMed  Google Scholar 

  58. Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 175–85

    Article  CAS  PubMed  Google Scholar 

  59. Banerjee M, Younis N, Soran H. Vildagliptin in clinical practice: a review of literature. Expert Opin Pharmacother 2009; 10: 2745–57

    Article  CAS  PubMed  Google Scholar 

  60. He YL, Liqueros-Saylan M, Sunkara G, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the anti-hypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008; 48: 85–95

    Article  CAS  PubMed  Google Scholar 

  61. Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009; 54: 516–23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. Hypertension 2009; 54: 468–70

    Article  CAS  PubMed  Google Scholar 

  63. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009; 26: 249–62

    Article  CAS  PubMed  Google Scholar 

  64. Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009; 26: 488–99

    Article  CAS  PubMed  Google Scholar 

  65. Dhillon S, Weber J. Saxagliptin. Drugs 2009; 69: 2105–14

    Google Scholar 

  66. Borja-Hart NL, Whalen KL. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. Ann Pharmacother 2010; 44: 1046–53

    Article  CAS  PubMed  Google Scholar 

  67. LaSalle JR. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. Postgrad Med 2010; 122: 144–52

    Article  PubMed  Google Scholar 

  68. Patel C, Li L, Komoroski B, Boulton D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and metformin inhealthy subjects [abstract no. 213]. 2007 Annual Meeting of the American College of Clinical Pharmacy; 2007 Oct 14-17; Denver (CO) [online]. Available from URL: http://www.pharmacotherapy.org/pdf/free/ACCP_Abstracts_Fall2007.pdf [Accessed 2010 Jul 10]

  69. Patel C, Li L, Komoroski B, Boulton D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and pioglitazone in healthy subjects [abstract no. 226]. 2007 Annual Meeting of the American College of Clinical Pharmacy; 2007 Oct 14-17; Denver (CO) [online]. Available from URL: http://www.pharmacotherapy.org/pdf/free/ACCP_Abstracts_Fall2007. pdf [Accessed 2010 Jul 10]]

  70. Patel C, Li L, Komoroski B, Boulton D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and glyburide in healthy subjects [abstract no. 212]. 2007 Annual Meeting of the American College of Clinical Pharmacy; 2007 Oct 14-17; Denver (CO) [online]. Available from URL: http://www.pharmacotherapy.org/pdf/free/ACCP_Abstracts_Fall2007.pdf [Accessed 2010 Jul 10]

  71. Girgis S, You X, Li L, et al. Effect of simvastatin on the pharmacokinetics of saxagliptin in healthy subjects [abstract no. 28]. J Clin Pharmacol 2007; 47(9): 1188 [online]. Available from URL: http://jcp.sagepub.com/cgi/reprint/47/9/1183 [Accessed 2010 Jun 1]

    Google Scholar 

  72. Boulton DW, Brenner E, Royzman K, et al. Effect of ketoconazole on the pharmacokinetics of saxagliptin in healthy subjects [abstract no. 89]. J Clin Pharmacol 2007; 47(9): 1203 [online]. Available from URL: http://jcp.sagepub.com/cgi/reprint/47/9/1183 [Accessed 2010 Jun 1]

    Google Scholar 

  73. Girgis S, Patel CG, Li L, et al. Effect of diltiazem on the pharmacokinetics of saxagliptin in healthy subjects [abstract no. 72]. J Clin Pharmacol 2007; 47(9): 1199 [online]. Available from URL: http://jcp.sagepub.com/cgi/reprint/47/9/1183 [Accessed 2010 Jun 1]

    Google Scholar 

  74. Boulton DW, Li L, Patel CG, et al. No pharmacokinetic interaction between saxagliptin and digoxin in healthy subjects [abstract no. PIII-69]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S93 [online]. Available from URL: http://www.nature.com/clpt/journal/v83/n1s/pdf/clpt200846a.pdf [Accessed 2010 Jun 1]

    Google Scholar 

  75. Boulton DW, Adams D, Li L, et al. Magnesium and aluminium hydroxides plus simethicone, famotidine, or omeprazole do not meaningfully affect the pharmacokinetics of saxagliptin in healthy subjects [abstract no. PIII-68]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S92–3 [online]. Available from URL: http://www.nature.com/clpt/journal/v83/n1s/pdf/clpt200846a.pdf [Accessed 2010 Jun 1]

    Google Scholar 

  76. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32: 1649–55

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611–22

    Article  CAS  PubMed  Google Scholar 

  78. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94(12): 4810–9

    Article  CAS  PubMed  Google Scholar 

  79. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin addedtoasubmaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63: 1395–406

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2008; 9: 402–13

    CAS  PubMed  Google Scholar 

  81. Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009; 10: 503–12

    Article  CAS  PubMed  Google Scholar 

  82. Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther 2010; 48: 46–58

    Article  CAS  PubMed  Google Scholar 

  83. Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009; 49: 1210–9

    Article  CAS  PubMed  Google Scholar 

  84. Argyrakopoulou G, Doupis J. DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. Adv Ther 2009; 26: 272–80

    Article  CAS  PubMed  Google Scholar 

  85. Karim A, Fleck P, Harris S, et al. Lack of pharmacokinetic interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects [abstract]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S14

    Article  Google Scholar 

  86. Karim A, Fleck P, Harris S, et al. Effect of fluconazole, ketoconazole, and gemfibrozil on the pharmacokinetics of alogliptin benzoate (SYR-322) in healthy subjects [abstract no. 105]. J Clin Pharmacol 2007; 47(9): 1207 [online]. Available from URL: http://jcp.sagepub.com/cgi/reprint/47/9/1183 [Accessed 2010 Jun 1]

    Google Scholar 

  87. Karim A, Chiselko P, Fleck P, et al. Lackofeffectofcyclosporine on the single dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects [abstract]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S13

    Google Scholar 

  88. Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63: 46–55

    Article  CAS  PubMed  Google Scholar 

  89. Pratley RE, Reusch JE, Fleck PR, et al., Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pio-glitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009; 25: 2361–71

    Article  CAS  PubMed  Google Scholar 

  90. Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009; 57(11): 2011–9

    Article  PubMed  Google Scholar 

  91. Karim A, Harris S, Fleck P, et al. Assessment of drug interaction between alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 in-hibitor, and warfarin at steady state [abstract no. 106]. J Clin Pharmacol 2007; 47(9): 1207 [online]. Available from URL: http://jcp.sagepub.com/cgi/reprint/47/9/1183 [Accessed 2010 Jun 1]

    Google Scholar 

  92. Karim A, Fleck P, Harris S, et al. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin inhealthy subjects [abstract]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S12–3

    Article  Google Scholar 

  93. Karim A, Copa A, Fleck P, et al. Effects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (ORTHO-NOVUM(R) 1/35) in healthy adult female subjects [abstract]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S13

    Google Scholar 

  94. Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Curr Opin Invest Drugs 2009; 10: 1091–104

    CAS  Google Scholar 

  95. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010; 19: 133–40

    Article  CAS  PubMed  Google Scholar 

  96. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; 38: 667–78

    Article  CAS  PubMed  Google Scholar 

  97. Graefe-Mody EU, Padula S, Ring A, et al. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009; 25: 1963–72

    Article  CAS  PubMed  Google Scholar 

  98. Graefe-Mody U, Ring A, von Eynatten M, Woerle HJ. Linagliptin has no pharmacokinetic interaction with commonly prescribed oral antidiabetic drugs [abstract]. 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension; 2010 May 13–16; Prague [online]. Available from URL: http://www.comtecmed.com/codhy/2010/abstracts150.aspx [Accessed 2010 Jul 5]

  99. Graefe-Mody U, Friedrich C, Brand T, et al. Linagliptin has no pharmacokinetic interaction with drugs commonly used in patients with cardiac disorders [abstract]. 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension; 2010 May 13–16; Prague [online]. Available from URL: http://www.comtecmed.com/codhy/2010/abstracts150.aspx [Accessed 2010 Jul 5]

  100. Graefe-Mody U, Huettner S, Stahle H, et al. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther 2010; 48: 367–74

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to André J. Scheen.

Additional information

An erratum to this article is available at http://dx.doi.org/10.2165/11534840-000000000-00000.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheen, A.J. Dipeptidylpeptidase-4 Inhibitors (Gliptins). Clin Pharmacokinet 49, 573–588 (2010). https://doi.org/10.2165/11532980-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11532980-000000000-00000

Keywords

Navigation